Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Receives $190m For New Influenza A(H1N1) Virus Vaccine
The order is a part of present pandemic stockpile contract between Sanofi and the US government that allows HHS to purchase vaccines for viruses with pandemic potential. Besides
The order is a part of present pandemic stockpile contract between Sanofi and the US government that allows HHS to purchase vaccines for viruses with pandemic potential. Besides
The new manufacturing plant is expected to be completed by 2012. The company will target Asian eye care market for diseases like glaucoma, eye infections, eye inflammation and
LITHE study, fifth international Phase III study in the extensive Actemra clinical development program, also showed that a greater proportion of patients treated with Actemra in combination with
Bayer plans to familiarize US growers with the features, benefits, and the varieties of the new technology. The company initially plans to offer two high-yielding Gly Tol cotton
Shionogi’s treatment is said to be effective even after 48 hours from the emergence of symptoms, unlike the “Tamiflu” influenza medication, which must be administered within 48 hours.
HHS is also in talks with other manufacturers to increase capacity. These manufacturers will receive another $150 million to produce pilot lots of vaccine and to pay for
The agreement will be finalized by the end of May 2009. NanoTherapies is engaged in the development of life-changing therapies for cancer treatment based on an evolving set
Hologic’s planned importation, use, sale or offer to sell of Adiana system will infringe various patents owned by Conceptus including U.S. Patent Nos. 7506650, 7428904, 7237552, 6709667 and
Effective July 2009, Drug Discovery Research facility in Hyderabad will be known as Aurigene – Hyderabad. Thus, Aurigene will now operate from two locations: Bangalore and Hyderabad. In
As part of this acquisition, NuSil will transfer the manufacturing of the Bluestar Silicones pharmaceutical Simethicone business to NuSil’s FDA registered facility in Bakersfield, California. The company will